News

ReAlta Life Sciences Closes $20M Series A3 Financing to Advance Multiple Programs into Phase 2 Trial

ReAlta Life Sciences, Inc., announced that the Company has successfully closed a Series A3 financing of $20 million. The financing was led by Marathon Pharma, with support from existing Series A investors and new, undisclosed investors. Funding obtained in this financing will advance multiple programs addressing ALI and HIE, including lead candidate RLS-0071, into Phase 2 clinical trials.

“The additional capital raised will support the advancement of our lead candidate, RLS-0071, into Phase 2 programs for multiple indications,” said Ulrich Thienel, M.D., Ph.D., ReAlta’s Chief Executive Officer. “This funding also allows us to bring our second compound into clinical development and leverage its unique capabilities to address new life-threatening medical needs. We appreciate our investors’ continued confidence in our platform and pipeline.”

ReAlta is advancing a new class of anti-inflammatory therapies based on its EPICC platform that leverages a billion years of evolution with a dual targeting mechanism that inhibits components of the complement cascade and cellular inflammatory processes. The Company’s lead compound RLS-0071 is in development to address hospital-based acute inflammatory conditions, including acute lung injury (ALI) and severe birth asphyxia or hypoxic ischemic encephalopathy (HIE), that could respond to the compound’s swift, powerful inhibition of complement and neutrophil recruitment and activation. ReAlta is currently conducting a Phase 1 trial in healthy volunteers for RLS-0071, as well as a separate proof of concept study to evaluate RLS-0071 as a therapy for ALI in hospitalized COVID-19 subjects. In addition, ReAlta is advancing the second compound emerging from its proprietary EPICC technology platform, RLS-0088, through IND-enabling studies later this year.

Recent News

07/01/2025

ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer

ISOThrive Inc., a clinical-stage biopharmaceutical company, announced interim results from a Phase 2 study of its lead candidate, ISOT-101, for treatment of Non-Erosive Reflux Disease (NERD). The data showed positive trends in addressing heartburn frequency and symptom severity among proton pump inhibitor (PPI) partial-responders (PR), a patient population with major unmet medical need. These positive

07/01/2025

Gary Lowenthal Joins Focused Ultrasound Foundation’s Council

The Focused Ultrasound Foundation is pleased to welcome Gary Lowenthal to its Council, a dedicated group of goodwill ambassadors who work closely with the Board of Directors and staff to provide advice and assist with raising funds and building awareness. Mr. Lowenthal is a retired educator, entrepreneur, and executive with a career spanning education, international service,

06/25/2025

Liquet Medical Closes Oversubscribed Seed Round to Launch Pilot Study Evaluating Real-Time Hemodynamic Monitoring

Liquet Medical, a clinical-stage medical device company developing the Versus™ Catheter — a first-of-its-kind dual-tipped catheter system cleared by the FDA for controlled and selective infusion of fluids into the pulmonary vasculature and hemodynamic monitoring — announced the successful and oversubscribed close of its Seed funding round, which officially closed in May 2025. The capital